Blog
.jpeg)
OXIWAVE-HEPA 8% Infusion: Amino Acid Supplementation for Nutritional Support
- 24-09-2026
Amino acids are essential building blocks involved in protein synthesis, tissue maintenance, growth, and several important metabolic processes. When nutritional requirements are increased or cannot be adequately met through normal dietary intake, healthcare professionals may consider appropriate nutritional supplementation based on the patient's clinical condition.
OXIWAVE-HEPA 8% Infusion is an amino acid formulation from Intra Life, supplied as an intravenous infusion in a 200 ml pack. The product contains selected amino acids including L-Isoleucine, L-Leucine, L-Lysine, and L-Methionine. It is indicated for amino acid supplementation to support muscle recovery, protein synthesis, growth, and nutritional deficiency management. The official product page identifies it as an 8% w/v amino acid intravenous preparation intended for administration under medical supervision.
What is OXIWAVE-HEPA 8% Infusion?
OXIWAVE-HEPA 8% Infusion is an amino acid nutritional infusion formulated to provide amino acids through intravenous administration.
The composition provided for the product includes:
- L-Isoleucine USP – 1.040 g
- L-Leucine USP – 1.309 g
- L-Lysine Monoacetate equivalent to Lysine USP – 0.688 g
- L-Methionine USP – 0.110 g
The product is supplied in a 200 ml infusion pack. According to the official Intra Life product information, OXIWAVE-HEPA 8% is an Amino Acids 8% w/v Injection/IV infusion solution for human use and administration under medical supervision.
OXIWAVE-HEPA 8% Infusion Composition
L-Isoleucine USP
L-Isoleucine is one of the branched-chain amino acids (BCAAs) and contributes to normal protein metabolism. Amino acids such as isoleucine are used by the body as substrates for protein synthesis and other metabolic processes.
OXIWAVE-HEPA 8% contains L-Isoleucine USP 1.040 g as part of its amino acid formulation.
L-Leucine USP
L-Leucine is another branched-chain amino acid and is an important amino acid involved in protein metabolism and protein synthesis.
The formulation contains L-Leucine USP 1.309 g, providing an amino acid component relevant to nutritional and protein-support requirements.
L-Lysine
L-Lysine is an essential amino acid that the body cannot produce in sufficient amounts and therefore needs to obtain through dietary or nutritional sources.
OXIWAVE-HEPA 8% contains L-Lysine Monoacetate equivalent to L-Lysine USP 0.688 g.
L-Methionine USP
L-Methionine is an essential amino acid involved in normal protein synthesis and several metabolic pathways.
The product contains L-Methionine USP 0.110 g as part of its amino acid composition.
OXIWAVE-HEPA 8% Infusion Uses
The product information provided by Intra Life indicates OXIWAVE-HEPA 8% Infusion for amino acid supplementation to support:
- Muscle recovery
- Protein synthesis
- Growth
- Nutritional deficiency management
Amino acid supplementation may form part of a broader nutritional management plan when nutritional requirements cannot be adequately met through regular intake. The exact clinical use, dose, infusion rate, and duration should be determined by a qualified healthcare professional based on the patient's nutritional and medical requirements.
How Does OXIWAVE-HEPA 8% Infusion Work?
Amino acids serve as fundamental substrates for protein synthesis. Once administered intravenously, the amino acids enter the circulating amino acid pool without requiring gastrointestinal absorption.
They can then be utilized by the body for protein synthesis and other metabolic functions. In clinical nutritional support, amino acid solutions may be used alongside appropriate energy, fluid, electrolytes, vitamins, and other nutrients depending on the patient's nutritional requirements.
OXIWAVE-HEPA 8% therefore provides a selected combination of amino acids through intravenous administration as part of nutritional support.
Benefits of OXIWAVE-HEPA 8% Infusion
1. Provides Amino Acid Supplementation
OXIWAVE-HEPA 8% supplies selected amino acids in an intravenous formulation, helping provide amino acid substrates when supplementation is clinically required.
2. Supports Protein Synthesis
Amino acids are the building blocks required for protein synthesis. Adequate amino acid availability is therefore important for maintaining normal protein metabolism.
3. Supports Muscle Recovery
The formulation contains L-Leucine and L-Isoleucine, which are branched-chain amino acids involved in protein metabolism. As indicated by the product information, the formulation is intended to support muscle recovery.
4. Supports Nutritional Management
Amino acid supplementation may be incorporated into nutritional management when dietary intake does not adequately meet nutritional requirements.
5. Supports Growth and Protein Requirements
Amino acids contribute to normal protein formation and are important for growth and tissue maintenance. OXIWAVE-HEPA 8% is indicated to support growth and nutritional requirements when clinically appropriate.
OXIWAVE-HEPA 8% Infusion in Nutritional Support
Nutritional requirements can vary considerably depending on age, body weight, health status, nutritional intake, metabolic requirements, and clinical circumstances.
When oral or enteral nutrition is inadequate or cannot sufficiently meet nutritional requirements, healthcare professionals may consider parenteral nutritional support. Intravenous amino acid solutions can provide amino acids directly into the bloodstream as part of an appropriately planned nutritional regimen.
OXIWAVE-HEPA 8% can therefore be considered within the context of physician-directed nutritional management where amino acid supplementation is required.
OXIWAVE-HEPA 8% Infusion and Muscle Recovery
Protein and amino acids play an important role in maintaining and rebuilding body tissues. Leucine and isoleucine are branched-chain amino acids involved in protein metabolism.
Because OXIWAVE-HEPA 8% contains these amino acids, its stated indication includes support for muscle recovery and protein synthesis.
However, intravenous amino acid infusion is a medical nutritional intervention and should not be considered a substitute for a balanced diet or routine sports nutrition product. Its use should be based on an appropriate clinical assessment.
Administration of OXIWAVE-HEPA 8% Infusion
OXIWAVE-HEPA 8% is administered intravenously under medical supervision. It is not intended for self-administration.
The appropriate dose, infusion rate, and duration can depend on several factors, including:
- Age and body weight
- Nutritional requirements
- Clinical condition
- Protein and nitrogen requirements
- Fluid and electrolyte status
- Hepatic and renal function
- Other nutritional therapy
- Relevant laboratory parameters
A qualified healthcare professional should determine the appropriate administration protocol.
Safety and Precautions
Because OXIWAVE-HEPA 8% is an intravenous amino acid infusion, it should be administered only by qualified healthcare professionals.
Medical assessment may be particularly important in individuals with significant renal or hepatic impairment, amino acid metabolism disorders, fluid or electrolyte abnormalities, or other conditions that may affect nutritional therapy.
Patients should not self-administer the product. Healthcare professionals should review the approved prescribing information for contraindications, precautions, interactions, adverse reactions, and special-population considerations before administration.
OXIWAVE-HEPA 8% Infusion Product Information
| Product Information | Details |
|---|---|
| Product Name | OXIWAVE-HEPA 8% Infusion |
| Dosage Form | Intravenous Infusion |
| Strength | Amino Acids 8% w/v |
| L-Isoleucine USP | 1.040 g |
| L-Leucine USP | 1.309 g |
| L-Lysine Monoacetate equivalent to Lysine USP | 0.688 g |
| L-Methionine USP | 0.110 g |
| Indication | Amino acid supplementation for muscle recovery, protein synthesis, growth and nutritional deficiency management |
| Packing | 200 ml |
| Route | Intravenous |
| Administration | Under medical supervision |
The product page from Intra Life confirms the 200 ml pack, amino acid 8% w/v formulation, intravenous route, and medical-supervision requirement.
Frequently Asked Questions About OXIWAVE-HEPA 8% Infusion
What is OXIWAVE-HEPA 8% Infusion?
OXIWAVE-HEPA 8% is an 8% w/v amino acid intravenous infusion supplied in a 200 ml pack for medical use under professional supervision.
What is OXIWAVE-HEPA 8% Infusion used for?
It is indicated for amino acid supplementation to support muscle recovery, protein synthesis, growth, and nutritional deficiency management.
What is the composition of OXIWAVE-HEPA 8%?
It contains L-Isoleucine USP 1.040 g, L-Leucine USP 1.309 g, L-Lysine Monoacetate equivalent to Lysine USP 0.688 g, and L-Methionine USP 0.110 g.
How is OXIWAVE-HEPA 8% administered?
It is administered intravenously under medical supervision. It should not be self-administered.
What is the pack size of OXIWAVE-HEPA 8%?
OXIWAVE-HEPA 8% Infusion is supplied in a 200 ml pack.
Does OXIWAVE-HEPA 8% support protein synthesis?
The amino acids supplied by the formulation serve as substrates involved in protein synthesis. The product is indicated to support protein synthesis and nutritional requirements.
Is OXIWAVE-HEPA 8% a nutritional supplement for routine use?
It is an intravenous pharmaceutical infusion, not a routine oral nutritional supplement. Its use should be determined by a qualified healthcare professional based on the patient's clinical and nutritional requirements.
Conclusion
OXIWAVE-HEPA 8% Infusion is an amino acid-based intravenous formulation from Intra Life, supplied in a 200 ml pack. It contains L-Isoleucine, L-Leucine, L-Lysine, and L-Methionine and is indicated for amino acid supplementation to support muscle recovery, protein synthesis, growth, and nutritional deficiency management.
By providing selected amino acids through intravenous administration, OXIWAVE-HEPA 8% can form part of physician-directed nutritional support when amino acid supplementation is clinically required. As an IV pharmaceutical product, it should be administered only under appropriate medical supervision and according to the approved prescribing information.